Grounded in science, guided by patients.
About Mesenkia
Mesenkia is a pre-clinical company developing the next-generation biological drug candidates designed to treat the aggressive brain tumor glioblastoma. Mesenkia is founded on world leading science from Uppsala University and the University of Tokyo originating from decades of collaborations dedicated to finding the root cause for tumor pathogenesis. The founders identified HVEM signaling as crucial for glioblastoma pathogenesis and developed a technology for disrupting the pathway.
Our Science
200,000+
patients affected each year
~15 mo
median survival today
$5.7B
market by 2033
2030
first-in-Human targeted
News
Researchers have identified HVEM as a promising therapeutic target in mesenchymal glioblastoma...
Kohei Miyazono has been elected as a new member to the Academy’s class for medical sciences at the royal ...
The US patent application IP001 has received an allowance for protection of our novel HVEM antagonistic single domain antibodies.
Mesenkia Therapeutics has secured an investment from Almi Invest as part of a SEK 5.6 million financing round. The ...
